Thompson Cancer Survival Center – Clinical Trials
Clinical Trials
Clinical trials are research studies designed to discover new ways to treat different cancers and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.
Thompson was the first to bring cancer clinical trials to East Tennessee over 25 years ago. Today, Thompson’s clinical trials department is under the leadership of David Chism, MD, and Kristi Simcox, BS, CCRP, System Director of Clinical Research. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.
Thompson Cancer Survival Center offers clinical trials at the following Thompson Oncology Group locations:
- Blount
- Downtown Knoxville
- Lenoir City
- Oak Ridge
- West Knoxville
- Thompson Proton Center
Our Team
Name | Title | Contact Info |
David Chism, MD | Medical Director of Clinical Research | [email protected] | 865-331-1812 |
Ryan Grover, MD | Medical Director of Thompson Proton Center | [email protected] | 865-862-1600 |
Kristi Simcox, BS, CCRP | Systems Director of Clinical Research | [email protected] | 865-331-4985 |
Jessica Severt, RN, BSN | Study Coordinator | [email protected] | 865-331-4966 |
Ashley Lyons, RN | Study Coordinator | [email protected] | 865-331-2586 |
Sarah France, RN | Study Coordinator | [email protected] | 865-331-2587 |
Casey M., BS | Study Coordinator, Thompson Proton Center | [email protected] | 865-331-8216 |
Christina Haller | Regulatory Specialist | [email protected] | 865-331-1902 |
Catherine Duke-Taylor, BS | Study Coordinator, Thompson Proton Center | [email protected] | 865-331-8215 |
Active Medical Oncology Clinical Trials
Esophageal
Protocol Number | NCT Number | Title | Principal Investigator |
NRG-GI006 | NCT03801876 | Phase iii randomized trial of proton beam therapy (pbt) versus intensity modulated photon radiotherapy (imrt) for the treatment of esophageal cancer | David Chism, MD |
Leukemia/Lymphoma
Protocol Number | NCT Number | Title | Principal Investigator |
M22-128 | NCT06508658 | A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | David Chism, MD |
Melanoma
Protocol Number | NCT Number | Title | Principal Investigator |
EA6141 | NCT02339571 | Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | David Chism, MD |
Non-Small-Cell Lung Cancer
Protocol Number | NCT Number | Title | Principal Investigator |
V940-002 | NCT06077760 | A PA Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002) | David D. Chism, MD |
V940-009 | NCT06623422 | A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) | David Chism, MD |
Active Proton Therapy Clinical Trials
Breast
Protocol Number | NCT Number | Title | Principal Investigator |
Breast Spot Delete | NCT04873362 | Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients with Pencil Beam Scanning Proton Therapy | Samantha |
Esophageal
Protocol Number | NCT Number | Title | Principal Investigator |
Head & Neck Spot Delete | NCT06183268 | Evaluation of Radiobiological Effects in Skin Toxicities for Head and Neck Cancer Patients with Pencil Beam Scanning Proton Therapy | Samantha Hedrick, PhD |
Registry
Protocol Number | NCT Number | Title | Principal Investigator |
REG001-09 | NCT01255748 | Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy | Ryan Grover, MD |
Coming Soon
Contact Us
Clinical Research Office
Thompson Cancer Survival Center
1915 White Avenue
Knoxville, TN 37916
Phone: (865) 331-1812
Monday – Friday, 8:00 am – 4:30 pm
Thompson Proton Center
6450 Provision Cares Say
Knoxville, TN 37909
Phone: (865) 862-1600
Monday – Wednesday, 8:00 am – 6:00 pm
Thursday, 8:00 am – 5:30 pm
Friday, 8:00 am – 5:00 pm